Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

A inhibitor, PPI-668, with and without ribavirin.

Further, data from other Boehringer Ingelheim studies will be presented at AASLD. The aim of these studies is to better understand faldaprevir's drug-drug interaction profile in patients who are taking birth control and common anti-addiction medications. Additionally, a study evaluating faldaprevir in patients who have renal impairment will also be presented. Studies have shown that there is a higher prevalence of chronic kidney disease, also known as renal impairment, in patients with HCV making it important to understand the activity of HCV treatments in this population.  

Faldaprevir and deleobuvir are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Abstracts from The Liver Meeting® can be accessed on the AASLD website at www.aasld.org.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to cure. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso™ and HCVerso®.

Faldaprevir is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso is a multi-study Phase 3 trial program that evaluates faldaprevir combined with PegIFN/RBV. The four trials that make up this program study the combination in treatment-naive, treatment-experienced and HIV/HCV coinfected patients with chronic genotype-1 HCV. Deleobuvir is an investigational NS5B non-nucleoside pol
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015 IRIDEX ... will release its second quarter 2015 financial results after ...   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/30/2015)... 30, 2015  Unichem Pharmaceuticals ( USA ... Hydrochlorothiazide tablets 25 mg 1000-count bottle to the consumer ... measure due to the identification of a Clopidogrel tablet ... The risk associated with mistakenly taking a Clopidogrel ... probability of experiencing Clopidogrel,s side effects which include bleeding ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... MISSISSAUGA, Ontario, June 22, 2011 CardioGenics Holdings ... magnetic beads business unit, which develops ultra sensitive ... its Canadian subsidiary, Luxspheres Inc. The beads business ... Company,s CardioGenics Inc. Canadian subsidiary ("CardioGenics"), will now ...
... N.J., June 22, 2011 ... Co. Ltd., and an international specialty pharmaceutical company, today ... Food and Drug Administration (FDA) for Rectiv™ (nitroglycerin) Ointment ... pain associated with chronic anal fissures.  Rectiv will be ...
Cached Medicine Technology:CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 2CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 3ProStrakan Receives FDA Approval for Rectiv™ for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures 2ProStrakan Receives FDA Approval for Rectiv™ for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures 3
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, Sigma Theta ... Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. Key nurse ... , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit of Human ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... new industry players to know in predictive health analytics , Jvion continues ... technologies. The firm creates predictive software that targets patient and population level illness ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... There’s no ... possible, even when it comes time to cook the next meal, making July the ... July by practicing best grilling tips and recipes. , Make the next cookout different ...
(Date:7/31/2015)... PA (PRWEB) , ... July 31, 2015 , ... M3 ... is excited to launch three new Board Exam Courses. , The additions of ... Doc Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries ... wedding cakes with custom designs, making life just a little bit sweeter for ... cakes for each customer who orders one. , The bakery provides a full line ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... of One Couple,s Struggle with Alzheimer,s , , WASHINGTONVILLE, N.Y., ... comfort the over 5 million Americans currently living with Alzheimer,s disease ... is proud to announce the release of her book, "Released to ... by iUniverse ). , , "Released to the Angels" ...
... , AUSTIN, Texas, June 2 Rules-Based Medicine, Incorporated ... Tony Barnes, Ph.D., MBA, has joined the Company as ... marketing and operational leadership as RBM commercializes new biomarker-based ... established provider of multiplex biomarker assays for improved drug ...
... effort to enroll women in revolutionary initiative to eradicate breast cancer ... The Avon Foundation and the Dr. Susan Love Research Foundation are ... Women, ( www.armyofwomen.org ) will be supported by AARP, ... are proud and excited to have received the AARP,s support," says ...
... Health Solutions, Inc. (Nasdaq: STRM ) announced today that ... the period ended April 30, 2009 on Tuesday, June 9, 2009 ... and web cast to review the results on Tuesday, June 9 ... the call by dialing (800) 860-2442 or (412) 858-4600, or can ...
... , ... death of abortionist, George Tiller, the American people and those around the world will have ... one unaffiliated criminal speak for an entire movement, or do the actions of hundreds of ... ...
... ... new CE/CEU course entitled A Review of Pain Screening Instruments for ... the Pain Patient to their extensive online library of nationally-approved continuing ... workers. While there is an increase in the number of ...
Cached Medicine News:Health News:The Unexpected Gifts of Alzheimer's 2Health News:The Unexpected Gifts of Alzheimer's 3Health News:Rules-Based Medicine, Inc. Names Tony Barnes to Lead Expanding Diagnostics Business 2Health News:AARP to Support the Love/Avon Army of Women 2Health News:Streamline Health to Announce First Quarter Fiscal Year 2009 Financial Results on Tuesday, June 9, 2009 2Health News:Streamline Health to Announce First Quarter Fiscal Year 2009 Financial Results on Tuesday, June 9, 2009 3Health News:The Killing of George Tiller: Video "Thine Eyes" Shows True Face of Pro-life Movement in the Face of 'Terrorist' Accusations 2Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 2Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 3Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: